As per MRFR analysis, the India Diabetic Retinopathy Market Size was estimated at 431 (USD Million) in 2023. The India Diabetic Retinopathy Market is expected to grow from 452.5 (USD Million) in 2024 to 1,098 (USD Million) by 2035. The India Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 8.392% during the forecast period (2025 - 2035).
The market for diabetic retinopathy in India is expanding significantly due to a number of important considerations. A major factor propelling this market is the growing incidence of diabetes in India, where a sizable portion of the population suffers from the condition.
A growing number of people are at risk for diabetic retinopathy since India has one of the highest rates of diabetes worldwide, according to the Indian Council of Medical Research. Additionally, as diabetic individuals' awareness of eye care has grown, proactive screening and diagnosis have increased, encouraging medical professionals to spend money on cutting-edge diagnostic tools.
The integration of telemedicine services to improve access to eye care in rural places is one of the market's opportunities to be investigated. Innovative teleophthalmology projects can help alleviate healthcare access discrepancies between rural and urban areas by allowing patients to receive follow-up care and consultations without having to travel great distances.
Furthermore, collaborations between the public and commercial sectors can make it simpler to obtain reasonably priced monitoring equipment and treatment alternatives, hence expanding treatment accessibility for larger populations. In India, recent trends show a growing trend towards the use of outpatient services and digital health platforms for the treatment of diabetic retinopathy.
AI-based diagnostic tools are becoming more and more popular as healthcare technology develops since they aid in early diagnosis and improved patient care. Furthermore, a cultural change towards emphasising eye health among diabetics is demonstrated by the growth of patient support organisations and community awareness initiatives.
These trends are reinforced by government programs and organisation education efforts emphasising the value of routine eye exams. All things considered, the Indian Diabetic Retinopathy Market shows encouraging trends in line with modernising healthcare and boosting patient involvement.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
The rise in diabetes prevalence in India is a significant driver for the India Diabetic Retinopathy Market. According to the Indian Council of Medical Research, the number of adults living with diabetes in India has nearly doubled from 31.7 million in 2009 to about 62 million in 2019.
This sharp increase correlates with an alarming rise in diabetic retinopathy cases, as approximately 25% of diabetics develop this complication. The Ministry of Health and Family Welfare has outlined that about 20% of patients with diabetes will ultimately develop some form of diabetic retinopathy, emphasizing the need for improved screening and treatment options.
This growing patient base underlines the market's potential for growth, as established organizations like the All India Ophthalmological Society are actively promoting awareness and advanced treatment protocols.
Ongoing advancements in treatment technologies are propelling growth in the India Diabetic Retinopathy Market. Innovations such as anti-vascular endothelial growth factor (anti-VEGF) therapy and laser treatment options have improved patient outcomes significantly.
The Indian Medical Association has reported that anti-VEGF treatments can reduce the risk of vision loss significantly, leading to increased adoption by healthcare providers.
With more than 1,300 hospitals across the country equipped with the latest technology for retinal treatments, the incidence rate of effective interventions is expected to rise. This progress is primarily driven by established pharmaceutical companies that invest in Research and Development (R&D) for novel therapies specifically targeting diabetic eye diseases.
The Indian government is proactively addressing the diabetes epidemic through various initiatives and awareness programs, which are crucial for the India Diabetic Retinopathy Market. Government schemes such as the National Programme for Prevention and Control of Diabetes, Cardio Vascular Diseases and Stroke aim to educate the public on the importance of regular eye screenings for diabetes patients.
The National Health Mission has also incorporated diabetic retinopathy screening into routine check-ups, aiming to reduce blindness caused by diabetes. According to reports, these national health campaigns have increased awareness by over 50% among diabetic patients regarding the need for eye examinations, thus expanding the market for diagnostic and treatment services in this sector.
India's rapidly aging population is increasingly becoming a significant driver for the India Diabetic Retinopathy Market. According to the Ministry of Statistics and Programme Implementation, the geriatric population is projected to reach 173 million by 2026.
This demographic is highly susceptible to chronic conditions, including diabetes and its complications. The Indian Geriatrics Society has reported that nearly 32% of elderly individuals suffer from diabetes, highlighting the urgency for specialized treatment and screening facilities.
As the number of elderly individuals continues to rise, healthcare providers are expected to ramp up their services, leading to a greater demand for diabetic retinopathy management and thereby fostering market growth.
The India Diabetic Retinopathy Market is characterized by its division into distinct types, mainly Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR), which reflect the varying stages of this eye condition.
NPDR, being the earlier stage of diabetic retinopathy, often presents without noticeable symptoms, leading to a large number of undiagnosed cases in the India population. This segment is significant as it serves as a critical marker for patient management and intervention strategies, particularly with the rising prevalence of diabetes in India.
On the other hand, PDR represents a more advanced stage of the disease where retinal blood vessels begin to proliferate abnormally, posing a higher risk of vision loss. This segment is important as it often necessitates urgent medical intervention and treatment to prevent serious complications, emphasizing the need for awareness and timely diagnosis within the Indian healthcare framework.
The demographic factors in India, particularly the increasing rates of obesity and sedentary lifestyles, contribute to an upward trend in diabetes-related eye diseases, thereby heightening the importance of effective screening and management strategies across both segments.
The segmentation of the India Diabetic Retinopathy Market into NPDR and PDR thus not only aids in understanding the disease's progression but also informs healthcare providers on tailored treatment approaches essential to cater to the specific needs of Indian patients facing these conditions.
Understanding this segmentation is critical for advancing the overall healthcare outcomes associated with diabetic retinopathy in India, given that timely care can significantly reduce the burden of severe vision loss within the population.
The distinction between NPDR and PDR can help healthcare authorities implement more focused public health strategies and allocate resources more effectively, addressing the unique challenges associated with each stage of diabetic retinopathy.
As diabetes prevalence continues to rise in India, the insights gained from examining these two types of diabetic retinopathy will be crucial for educating both patients and healthcare providers about the importance of regular eye examinations and the need for an integrated approach to diabetes management, ultimately playing a vital role in enhancing the quality of life for those affected.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the India Diabetic Retinopathy Market is characterized by a diverse range of therapeutic options aimed at addressing the increasing prevalence of this condition among diabetic patients in the region. Pharmacological Therapies primarily encompass modern injectable medications that target the underlying disease pathways, providing crucial options for managing retinal complications.
Laser Treatment plays a significant role, offering effective localized interventions to photocoagulate damaged retinal tissues and prevent further vision loss. Meanwhile, Surgery remains essential for advanced cases, where surgical procedures help to restore vision or prevent severe complications when other treatments are insufficient.
The growing awareness of diabetes and its complications is driving demand for these treatment modalities, and the segment is poised for growth as healthcare access improves across India.
With an increasing focus on Research and Development to innovate and enhance treatment efficacy, the Treatment segment is crucial in the Indian healthcare landscape as it strives to mitigate the impact of Diabetic Retinopathy on the population.
Furthermore, the segment faces challenges such as cost barriers and the need for specialized training among healthcare professionals, yet it presents significant opportunities for healthcare providers and patients alike.
The India Diabetic Retinopathy Market is significantly driven by the End-user segment, which encompasses various healthcare facilities that play a vital role in diagnosing and treating this condition. Hospitals and Clinics are particularly crucial as they provide comprehensive care and have access to advanced technologies for detecting diabetic retinopathy at early stages.
Many of these establishments have adopted innovative management technologies and treatment protocols, leading to improved patient outcomes. Ophthalmology Centers focus exclusively on eye care and are essential for specialized diagnosis and treatment, making them significant players in the management of diabetic retinopathy.
With the growing prevalence of diabetes in India, research initiatives within Research Institutes are vital for advancing knowledge and developing better therapeutic strategies, creating a pipeline for innovative treatment solutions.
This focus on research not only enhances clinical practices but also contributes to the overall growth of the India Diabetic Retinopathy Market by establishing new treatment paradigms and improving patient accessibility to care.
The collaborative efforts across these end-user types underpin the health sector's response to the increasing burden of diabetic retinopathy in the country, highlighting the intersection of healthcare demand and medical innovation.
The India Diabetic Retinopathy Market presents a dynamic and rapidly evolving landscape characterized by the increasing prevalence of diabetes and its associated complications. Diabetic retinopathy stands as one of the leading causes of blindness among adults in the country, driving demand for innovative treatment solutions and advancement in diagnostic technologies.
The competitive insights within this market reveal a strong focus among various players on enhancing their product offerings, investing in research and development, and forming strategic partnerships.
The emphasis on effective management of diabetic retinopathy through both pharmacological and non-pharmacological approaches has led to an intensified competitive atmosphere as companies strive to capture market share and meet the needs of healthcare providers and patients alike.
Additionally, collaborations between pharmaceutical companies, healthcare institutions, and research organizations are becoming increasingly common, aiming to accelerate innovation and improve patient outcomes in the growing Indian market.
Santen Pharmaceutical has a notable presence in the India Diabetic Retinopathy Market, emphasizing its commitment to providing high-quality ophthalmic solutions tailored to address diabetic eye disorders. The company's strategic focus on research and development has led to the introduction of specialized products that cater to the unique challenges faced by diabetic patients in India.
With a customer-centric approach, Santen Pharmaceutical has established strong relationships with healthcare professionals, fostering trust and brand loyalty. Furthermore, their dedication to incorporating the latest advancements in surgical techniques and ophthalmic care positions them as a leader in the segment.
The emphasis on education and awareness campaigns about diabetic retinopathy further strengthens their market presence, ensuring both patients and healthcare providers are informed about the importance of early detection and treatment.
Bayer also plays a pivotal role in the India Diabetic Retinopathy Market, with a robust portfolio of innovative therapies aimed at effectively managing this condition. The company's flagship products include intravitreal injections that have shown significant efficacy in treating diabetic macular edema and other diabetic retinopathy-related complications.
Bayer's extensive distribution network and strong relationships with ophthalmologists ensure that its products are readily accessible across various healthcare settings in India. Through strategic mergers and acquisitions, Bayer has enhanced its capabilities and broadened its market reach within the country.
The company is investing in educational initiatives to raise awareness about diabetic retinopathy among patients and healthcare providers alike, contributing to a more informed population that understands the importance of timely intervention.
Bayer's commitment to ongoing research and development in the field further solidifies its position as a key player in the Indian market, reflecting its strength and dedication to improving patient outcomes in diabetes-related eye health issues.
The India Diabetic Retinopathy Market has seen significant developments recently, driven by rising diabetes prevalence and advancements in treatment modalities. In September 2023, Bayer launched a new retinal therapy aimed at improving outcomes for diabetic retinopathy patients.
The Indian government has prioritized eye health, launching campaigns to enhance awareness and early detection of diabetic complications. Major pharmaceutical companies, including Santen Pharmaceutical, Novartis, and Roche, are increasing investments in Research and Development to innovate treatment solutions.
In July 2023, Sun Pharmaceuticals announced partnerships to enhance its portfolio for diabetic retina treatment, reflecting a collaborative push within the industry. Notably, there have been no recent mergers or acquisitions reported among the key players in this market.
Additionally, between 2021 and 2022, Dr. Reddy's Laboratories expanded its operations significantly to include a broader range of ophthalmic products, which bolstered its market presence. The growth in market valuation is fostering competition, pushing companies to enhance their product offerings and reach more patients.
As awareness grows and technology improves, the landscape of the India Diabetic Retinopathy Market will likely continue evolving rapidly.
| Report Attribute/Metric | Details |
| Market Size 2023 | 431.0(USD Million) |
| Market Size 2024 | 452.5(USD Million) |
| Market Size 2035 | 1098.0(USD Million) |
| Compound Annual Growth Rate (CAGR) | 8.392% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Santen Pharmaceutical, Bayer, Novartis, Bristol Myers Squibb, Dr. Reddy's Laboratories, Roche, Amgen, Torrent Pharmaceuticals, Abbott Laboratories, Sun Pharmaceuticals, Lupin Pharmaceuticals, Zydus Cadila, Pfizer, Regeneron Pharmaceuticals, Allergan |
| Segments Covered | Type, Treatment, End-user |
| Key Market Opportunities | Telemedicine for remote screenings, Advanced diagnostic technologies adoption, Increased diabetic population management, Collaborations with eye care providers, Rising awareness and education initiatives |
| Key Market Dynamics | rising diabetes prevalence, increasing awareness programs, technological advancements in screening, government initiatives for early detection, growing geriatric population |
| Countries Covered | India |
Frequently Asked Questions (FAQ) :
The India Diabetic Retinopathy Market was valued at 452.5 million USD in 2024.
The market is projected to reach 1098.0 million USD by 2035.
The market is expected to grow at a CAGR of 8.392% during the forecast period from 2025 to 2035.
In 2024, the Non-Proliferative Diabetic Retinopathy market was valued at 227.5 million USD.
The Proliferative Diabetic Retinopathy segment is projected to reach 565.0 million USD by 2035.
Major players include Santen Pharmaceutical, Bayer, Novartis, and Dr. Reddy's Laboratories, among others.
Emerging trends such as increased diagnosis and treatment accessibility are driving growth opportunities.
Challenges include limited awareness and accessibility to advanced treatment options in rural regions.
The Non-Proliferative Diabetic Retinopathy market is forecasted to grow significantly during this period.
The current global scenario could affect supply chains and the availability of key therapeutic options.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
